Leukaemia Trial, Not Yet Recruiting NCT07518940 Sponsor: Carmen Fava Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Not Yet Recruiting

NCT07518940
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older.
  • People who have been diagnosed with a myeloproliferative neoplasm (such as polycythemia vera, essential thrombocythemia, or low-risk primary myelofibrosis) or chronic myeloid leukemia, confirmed according to World Health Organization standards.
  • People whose condition and treatment have been stable for at least 8 weeks before enrolling.
  • People who are experiencing a meaningful level of fatigue, as measured by validated disease-specific questionnaires.
  • People whose overall health condition is suitable for taking part in a supervised exercise program of at least moderate intensity.
  • People who have no medical reasons preventing them from undergoing cardiopulmonary exercise testing (a test that measures how the heart and lungs respond to physical activity).
  • People who have not taken part in any structured exercise or rehabilitation program in the 3 months before enrolling.
  • People whose blood counts meet minimum safety levels (hemoglobin above 10 g/dL and platelets above 100,000 × 10⁹/L).
  • People who are able to understand and follow the study procedures.
  • People who have provided written consent to participate.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with unstable heart or cardiovascular conditions, including uncontrolled heart failure, a recent heart attack or ischemia, significant irregular heart rhythms, or unexplained fainting episodes.
  • People who have had a blood clot or serious bleeding episode within the 3 months before enrolling.
  • People with an active acute or ongoing chronic infection.
  • People with severe bone, joint, or neurological conditions that limit their ability to exercise or complete physical testing.
  • People with serious systemic illnesses, such as advanced kidney or liver failure, an active second cancer, or an uncontrolled psychiatric condition.
  • People whose overall clinical situation, in the treating doctor's judgment, could put their safety at risk or make it difficult to follow the study protocol.
  • People who have been assessed by a rehabilitation specialist as needing a dedicated primary rehabilitation program.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carmen Fava, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

Phone: 00390115082224

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Carmen Fava
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
1 September 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Feasibility: Adherence to Exercise Program; Feasibility: Retention Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov